Business Context and Reporting Period
This Form 8-K Current Report was filed by iBio, Inc. on May 7, 2026. The filing addresses corporate governance changes, specifically the appointment of a new director and the resignation of an existing director, effective May 7, 2026.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel changes and associated compensation arrangements.
Material Changes
- Board Appointment: Dr. Elizabeth Stoner, M.D., M.S., was appointed as a Class II director and member of the Compensation Committee, effective May 7, 2026. Her term expires at the 2028 annual meeting.
- Board Resignation: Evert Schimmelpennink resigned from the Board and the Compensation Committee effective immediately on May 7, 2026. The resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
- Compensation Structure: Dr. Stoner will receive an annual board fee of $40,000 and an annual committee fee of $7,500 for the fiscal year ending June 30, 2026. She is also eligible for a one-time stock option grant vesting over 36 months and other equity awards consistent with company policy.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of operational risks. It notes that Dr. Stoner has no family relationships with current directors or officers and no material interest in transactions requiring disclosure under Item 404(a) of Regulation S-K. A standard indemnification agreement was entered into with Dr. Stoner.
Investor Verification Checklist
- Verify Dr. Elizabeth Stoner's background and prior board service (e.g., Semma Therapeutics, Rhythm Pharmaceuticals, Merck) to assess potential conflicts of interest or strategic alignment.
- Confirm the total number of board seats and the composition of the Compensation Committee following the resignation of Evert Schimmelpennink.
- Review the specific terms of the stock option grant and equity awards for Dr. Stoner in future filings or proxy statements.
- Check for any subsequent press releases or filings regarding the rationale for Mr. Schimmelpennink's departure beyond the stated "no disagreement" clause.